Ono Pharmaceutical Co. said Friday it has signed a drug-discovery agreement with Array BioPharma Inc., based in Colorado.
Under the agreement, the two firms will seek to discover small molecule drug candidates targeting a series of kinases selected by Ono, the Osaka-based firm said.
Ono will be responsible for the clinical development and commercialization of new products emerging from the collaboration. It will also provide Array with research costs, development milestone payments and royalties.
A kinase is an enzyme that modifies other proteins by chemically adding phosphate groups to them.